Drug Trial Radar · NCT00134667
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
Last checked: Nov 20, 2026Latest source record: Jan 15, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
360
Actual
Start
Mar 2005
Primary completion
Not stated
Study completion Oct 2008
Sponsor
- Lead sponsor
- Eyetech PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Aug 25, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the eye and thereby stabilizing or improving vision when compared to Macugen alone. Patients must be recently diagnosed with predominantly classic wet AMD and must be eligible for PDT.
Conditions
- Age-Related Macular Degeneration
Interventions
Photodynamic Therapy (PDT) with Visudyne (verteporfin)Drug
Macugen (pegaptanib sodium)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Retina Centers, P.C., Northwest Location
Tucson, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.